Clinical Trial Detail

NCT ID NCT03199040
Title Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

triple-receptor negative breast cancer

Therapies

Durvalumab

Age Groups: senior adult

No variant requirements are available.